Skip to content
Biotechnology

Chiron AS Establishes State-of-the-Art Research Centre in Trondheim, Norway, Advancing Environmental Surveillance

ZeptoMetrix 2 mins read

TRONDHEIM, NORWAY / ACCESSWIRE / January 17, 2024 / Chiron AS, a leading producer of chemical reference materials headquartered in Trondheim, Norway, is pleased to announce the establishment of a state-of-the-art research centre dedicated to the enhanced surveillance of environmental pollutants.



This ground-breaking development, supported by an estimated 40 million NOK investment, reaffirms Chiron's commitment to advancing the field of environmental analysis.

The newly inaugurated research facility, which offers a 360-degree view of the Trondheim fjord, is equipped to address the most challenging pollutants of today, including microplastics and PFAS (commonly known as ‘forever chemicals'), and is poised to contribute significant research into environmental surveillance.

This strategic relocation follows Chiron's acquisition by Antylia Scientific in July 2023 and its successful incorporation into the ZeptoMetrix® Operating Division. The move to the new 1750 m2 premises aligns Chiron with Spex®, NSI Laboratories and High Purity Standards in strengthening the ZeptoMetrix Reference Material and Proficiency Testing portfolio.

"We are excited to embark on this journey of heightened environmental surveillance," Jon Eigill Johansen, Founder of Chiron AS, commented. "The establishment of our research centre highlights our commitment to scientific excellence. Through cutting-edge research and collaboration, we aim to support our mission to protect humans from undesired chemical exposure."

Evangeline Gonzalez, President of the ZeptoMetrix Operation Division, stated, "This investment reinforces our dedication to advancing environmental science. Chiron's state-of-the-art research centre adds a crucial dimension to the ZeptoMetrix portfolio. This means we are even more ready to support our lab and industry partners with critical innovation as they work to address ongoing environmental challenges."

About ZeptoMetrix®

ZeptoMetrix, an Antylia Scientific Company, is the industry leader and manufacturer for innovative solutions solving challenges in the evolving Diagnostic Microbiology Infectious Disease, Oncology market and Analytical Reference Materials for the Applied Markets. We focus on our customers' success by providing premium product quality, reliability, and expert technical knowledge, enabling our customers to develop and advance many applications across diagnostics, pharmaceutical, environmental, food and beverage industries. From in stock solutions to custom control and panel development through to launch, our scientific teams provide our customers with comprehensive, performance-oriented, and cost-effective products and services that positively impact the field of clinical diagnostics, analytical testing and contribute to a healthier world. ZeptoMetrix is an operating division of Antylia Scientific, a holding company of premier life science and diagnostic brands, including Cole-Parmer, Environmental Express and ZeptoMetrix.

Contact Information

Jennifer Button
Deputy Director
jenny.button@chiron.no
+44(0)7963508499

Related Files

Chiron AS Establishes State-of-the-Art Research Centre.pdf

SOURCE: Chiron AS

.

View the original press release on newswire.com.

More from this category

  • Biotechnology, Business Company News
  • 24/07/2024
  • 10:53
Jane Morgan Management

LTR Pharma Ltd (ASX:LTP) Completes A$10.5 million Placement to Expedite Commercialisation of SPONTAN

Sydney, Australia – 24 July 2024 – LTR Pharma Limited (ASX: LTP) ("LTR Pharma" or "the Company"), a company focused on improving men’s health through the clinical development and commercialisation of an innovative nasal spray treatment for Erectile Dysfunction ("ED") called SPONTAN®, is pleased to announce the successful completion of a A$10.5 million share placement to sophisticated and new institutional investors. The placement received demand significantly above the A$10.5 million raised. Key Highlights: Successful Fundraising: LTR Pharma has raised A$10.5 million through a private placement at an issue price of A$0.73 per share, representing a 13.2% discount to the 30-day…

  • Contains:
  • Agriculture Farming Rural, Biotechnology
  • 23/07/2024
  • 15:56
La Trobe University

Nation’s food security tackled through new institute

La Trobe University is paving the way for Australian food security, with the establishment of a new institute that will expand cutting-edge agricultural research and innovation. The La Trobe Institute for Sustainable Agriculture and Food (LISAF) officially launched today (23 July), to undertake research and innovation across the agri-food-health chain, aiming to enhance profitability for producers while also improving product quality and choice for consumers. LISAF Director Professor Tony Bacic said a key component of the Institute’s “paddock to gut” research was to enhance plant functionality, enabling food and medicinal crops to be grown in innovative ways and with new…

  • Biotechnology, Medical Health Aged Care
  • 22/07/2024
  • 12:56
Illumina

Research into psychedelic medicines to treat anxiety wins ANS Illumina Neurogenomics Award 2024

Genomic technologies to discover biological markers, within the blood, that could predict patient response to psychedelic medicines such as psilocybin. MELBOURNE, AUSTRALIA, 22 July 2024 - Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the winner of the annual Australasian Neuroscience Society (ANS) Illumina Neurogenomics Research Award as Dr Andrew Gibbons from the Department of Psychiatry, School of Clinical Sciences at Monash Health. “Psilocybin, a chemical produced by hallucinogenic mushrooms, is a psychedelic medicine that has shown to meaningfully reduce symptoms of generalized anxiety during psychotherapy for patients. However, not all patients respond.…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.